Stephen D. Wiviott
Brigham and Women's Hospital
6 papers in the Anchorcite directory, published between 2007 and 2018, cited 34,219 times in total.
ORCID profileResearch topics
- Acute Myocardial Infarction Research · 4 papers
- Antiplatelet Therapy and Cardiovascular Diseases · 2 papers
- Coronary Interventions and Diagnostics · 2 papers
- Lipoproteins and Cardiovascular Health · 2 papers
- Diabetes Treatment and Management · 1 paper
- Chronic Kidney Disease and Diabetes · 1 paper
Frequent co-authors
- Eugene Braunwald · 3 papers
- Sabina A. Murphy · 3 papers
- Robert Patrick Giugliano · 3 papers
- Witold Rużyłło · 2 papers
- Charles Michael Gibson · 2 papers
- Elliott Marshall Antman · 2 papers
- Julia Kuder · 2 papers
- Deepak L. Bhatt · 2 papers
Papers
- Prasugrel versus Clopidogrel in Patients with Acute Coronary SyndromesNew England Journal of Medicine · 2007 · 6,831 citations
BACKGROUND: Dual-antiplatelet therapy with aspirin and a thienopyridine is a cornerstone of treatment to prevent thrombotic complications of acute coronary syndromes and percutaneous coronary intervention. METHODS: To compare prasugrel, a new thienopyridine, with clopidogrel, we randomly assigned 13,608 patients with…
- Dapagliflozin and Cardiovascular Outcomes in Type 2 DiabetesNew England Journal of Medicine · 2018 · 6,600 citations
BACKGROUND: The cardiovascular safety profile of dapagliflozin, a selective inhibitor of sodium-glucose cotransporter 2 that promotes glucosuria in patients with type 2 diabetes, is undefined. METHODS: of body-surface area, new end-stage renal disease, or death from renal or cardiovascular causes)…
- Evolocumab and Clinical Outcomes in Patients with Cardiovascular DiseaseNew England Journal of Medicine · 2017 · 6,357 citations
BACKGROUND: Evolocumab is a monoclonal antibody that inhibits proprotein convertase subtilisin-kexin type 9 (PCSK9) and lowers low-density lipoprotein (LDL) cholesterol levels by approximately 60%. Whether it prevents cardiovascular events is uncertain. METHODS: We conducted a randomized, double-blind, placebo-controlled trial involving…
- Edoxaban versus Warfarin in Patients with Atrial FibrillationNew England Journal of Medicine · 2013 · 5,259 citations
BACKGROUND: Edoxaban is a direct oral factor Xa inhibitor with proven antithrombotic effects. The long-term efficacy and safety of edoxaban as compared with warfarin in patients with atrial fibrillation is not known. METHODS: We conducted a randomized, double-blind, double-dummy trial…
- Ezetimibe Added to Statin Therapy after Acute Coronary SyndromesNew England Journal of Medicine · 2015 · 4,600 citations
BACKGROUND: Statin therapy reduces low-density lipoprotein (LDL) cholesterol levels and the risk of cardiovascular events, but whether the addition of ezetimibe, a nonstatin drug that reduces intestinal cholesterol absorption, can reduce the rate of cardiovascular events further is not known.…
- Standardized Bleeding Definitions for Cardiovascular Clinical TrialsCirculation · 2011 · 4,572 citations
HomeCirculationVol. 123, No. 23Standardized Bleeding Definitions for Cardiovascular Clinical Trials Free AccessResearch ArticlePDF/EPUBAboutView PDFView EPUBSections ToolsAdd to favoritesDownload citationsTrack citationsPermissionsDownload Articles + Supplements ShareShare onFacebookTwitterLinked InMendeleyReddit Jump toSupplementary MaterialsFree AccessResearch ArticlePDF/EPUBStandardized Bleeding Definitions for Cardiovascular Clinical TrialsA Consensus Report From…
Metadata from OpenAlex (CC0).